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Abstract To discuss and share knowledge around
advances in the care of patients with thrombotic disorders,
the Third International Symposium of Thrombosis and
Anticoagulation was held in Sa˜o Paulo, Brazil, from
October 14–16, 2010. This scientific program was devel-
oped by clinicians for clinicians, and was promoted by four
major clinical research institutes: the Brazilian Clinical
Research Institute, the Duke Clinical Research Institute of
the Duke University School of Medicine, the Canadian
VIGOUR Centre, and the Uppsala Clinical Research
Center. Comprising 3 days of academic presentations and
open discussion, the symposium had as its primary goal to
educate, motivate, and inspire internists, cardiologists,
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hematologists, and other physicians by convening national
and international visionaries, thought-leaders, and dedi-
cated clinician-scientists. This paper summarizes the
symposium proceedings.
Keywords Thrombosis  Antithrombotic therapy 
Guidelines  Clinical research
Introduction
Importance of thrombosis
Venous and arterial thrombosis remains the most frequent
cause of death in western countries. Cardiovascular dis-
ease, including heart attack and stroke, accounts for more
than 50% of deaths (http://www.cdc.gov/nchs/fastats/
deaths.htm). Additionally, the presence of thromboembo-
lism is an adverse prognostic indicator in patients with
cancer, which is the second most common cause of death.
As a result, there is great interest in the development of
novel anticoagulant agents designed to reduce the risk of
first or recurrent thrombotic event while minimizing the
risk of bleeding. Arterial thrombosis is generally due to
platelet activation occurring at sites of vascular injury in
high-flow and high-sheer vessels. Generally, antiplatelet
agents are preferred for primary or secondary prevention of
arterial thrombosis because they inhibit platelet activation
induced by platelet binding at sites of vascular injury and
mediated by von Willebrand factor. Recent interest has
focused on the development of new and more potent
antiplatelet agents with special characteristics including
rapid on- and off-set of action, shorter half-lives, and more
potent inhibition of specific self-surface receptors includ-
ing the thrombin receptor.
Venous thrombosis is generally thought to be due to
activation of soluble coagulation proteins in low-flow areas
of the venous system. There are some parallels in the left
atrium of patients with atrial fibrillation (AF), suggesting
that treatments that are effective for prevention of venous
thrombosis will also be effective for prevention of systemic
embolization in patients with AF. Traditional agents for
prevention and treatment of venous thrombosis include
heparins, low-molecular-weight heparins (LMWH), pen-
tasaccharides, and a variety of parenteral anticoagulants
used infrequently in specific circumstances such as patients
with heparin-induced thrombocytopenia. Long-term ther-
apy has traditionally been provided by warfarin adminis-
tered to achieve an international normalized ratio (INR) of
2.0–3.0. The limitations of warfarin—including drug and
food interactions, variability within and between patients in
dosing requirements, a narrow therapeutic window, and the
need for frequent INR monitoring—have led to the
development of novel agents that lack some or all of these
characteristics. Dabigatran and rivaroxaban are two agents
that have been approved for several indications. Dabigatran
recently was approved in Canada and the United States for
prevention of systemic embolization in patients with AF.
These agents, if proven safe in phase IV studies, offer
significant advantages over warfarin for prevention of
systemic embolization. They are also the subject of studies
for secondary prevention of venous thrombosis. In this
setting, efficacy of both agents is comparable to warfarin.
Intensification of antithrombotic therapy has a cost.
There is clear evidence that bleeding rates increase as
patients are treated with more aggressive antithrombotic
regimens. Thus, when compared with warfarin alone,
bleeding risks increase in patients treated with aspirin and
warfarin, and further increase in patients treated with so-
called ‘‘triple therapy.’’ Risks of bleeding will undoubtedly
be even higher in patients who are treated with ‘‘quadruple
therapy,’’ as novel antiplatelet and antithrombotic agents
are brought to market.
There is also evidence that a therapeutic effect can be
achieved at lower doses of antithrombotic medications than
are currently employed for many indications. Thus, pro-
phylactic doses of pentasaccharide are as effective as
therapeutic doses of enoxaparin for prevention of throm-
botic and other vascular complications in patients with
unstable coronary syndromes. At prophylactic doses,
fondaparinux produces less bleeding than enoxaparin,
suggesting it may be a preferred agent for treatment in this
setting. The pentasaccharide study highlights current
thoughts suggesting that ‘‘de-intensification’’ should be
considered in selected patients because currently available
antithrombotics may maintain their ‘‘therapeutic effect’’ at
levels that are associated with a lower rate of ‘‘toxicity,’’
predominantly bleeding.
In summary, cardiovascular disease remains a leading
cause of death. Significant resources have been invested in
the design and evaluation of novel antithrombotic agents,
which are now being evaluated for prevention of both first
and recurrent thrombotic events in high-risk patients.
Demonstration that intensification of anticoagulation is
associated with enhanced bleeding risk has led to studies
that attempt to de-intensify antithrombotic therapy. Novel
agents offer the hope of simplicity of treatment with
reduced toxicity; however, their safety must be proven in
large patient groups.
ISTA
To discuss and share knowledge around advances in the
care of patients with thrombotic disorders, the Third
International Symposium of Thrombosis and Anticoagu-
lation (ISTA) was held in Sa˜o Paulo, Brazil, from October
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14–16, 2010. This scientific program was developed by
clinicians for clinicians, and was promoted by four major
clinical research institutes: the Brazilian Clinical Research
Institute (BCRI), the Duke Clinical Research Institute
(DCRI) of the Duke University School of Medicine, the
Canadian VIGOUR Centre (CVC), and the Uppsala Clin-
ical Research Center (UCR). It was also supported by the
Brazilian Societies of Internal Medicine, Cardiology,
Intervention Cardiology, Heart Failure, Nephrology,
Intensive Care Medicine, Hematology, Oncology, and
Vascular Surgery, by the Latin American Group of
Thrombosis and Hemostasis, and by the Anticoagulation
Forum from the United States. The chairmen of the
meeting were Dr. Renato D. Lopes and Dr. Richard C.
Becker, both from Duke University School of Medicine
and the Duke Clinical Research Institute, and Dr. David
Garcia from the University of New Mexico.
Comprising 3 days of academic presentations and open
discussion, the symposium had as its primary goal to
educate, motivate, and inspire internists, cardiologists,
hematologists, and health care providers by convening
national and international visionaries, thought-leaders, and
dedicated clinician-scientists to review the scientific evi-
dence in the area of thrombosis. The following is a sum-
mary of the symposium proceedings.
Platelet biology
Platelet biology and an advanced understanding of funda-
mental concepts governing the behavior of platelets, both
in terms of pathologic thrombotic events and the support of
normal hemostasis, comprise a vital part of identifying
targets for drug development and achieving optimal patient
care. There are four constructs or functional themes of
importance: platelet aggregation, platelet support of coag-
ulation, platelet support of vascular integrity, and platelet
support of vascular repair.
The initiation of coagulation is characterized by the
assembly of coagulation proteins on tissue factor-bearing
cells. This is followed by thrombin generation and, if of
sufficient quantity to cause platelet activation, platelet
aggregation, assembly of coagulation proteins, and a
‘‘burst’’ of thrombin generation with subsequent clot
propagation.
Platelet activation and aggregation occurring at a site of
vessel wall injury is characterized by three distinct popu-
lations of platelets. The first population is characterized by
expression of ligand receptors, which in turn facilitate
platelet aggregation. The second is characterized by the
expression of phosphatidylserine with support coagulation
protein assembly and thrombin generation. The third con-
sists of a population of platelets with predominantly
paracrine effects that are required for the important stage of
vessel wall healing. This latter population of platelets has
been underappreciated in considering the potential effects
of long-term, robust platelet inhibition with pharmacolog-
ical therapy.
Several recent observations shed new light on the
important interface between platelets and coagulation
protein activation within the developing thrombus. Spe-
cifically, the release of platelet polyphosphates has been
shown to activate factors XI and XII, facilitating thrombin
generation. More recent information also highlights the
role of polyphosphates, factor XI, and factor XII as triggers
of thrombosis that are not required for normal hemostasis.
These observations will likely prompt increasing interest in
new targets with the theoretical potential to uncouple
thrombosis and hemostasis.
The importance of platelets in both a reparative capacity
and as facilitators of inflammation highlights their pleo-
tropic capabilities. Despite being anuclear cells, megakar-
yocytes within the bone marrow respond to a variety of
signals, potentially being reprogrammed in the presence of
specific conditions. In addition, the recognition that acti-
vated human platelets splice pre-mRNA into mature tran-
scripts supports a highly dynamic capability. Whether
platelet antagonists can influence either programming at
the level of the megakaryocyte or peripheral circulation
splicing of pre-mRNA will require further investigation. It
is becoming increasingly clear that platelets no longer can
be viewed as passive bystanders to vascular events and
systemic conditions.
Measures of platelet function
For the last several decades, measurement of platelet
function has been used primarily for diagnosis of intrinsic
deficiencies of platelet hemostatic capacity. However,
more recent work has focused on platelet function testing
as a pharmacodynamic measure of response to platelet-
directed therapy. In the treatment of atherothrombosis,
inhibition of platelet activation and aggregation plays a
central role in attenuating thrombus formation and propa-
gation. Such antagonism of the atherothrombotic process is
vital for secondary prevention in patients with acute cor-
onary syndromes (ACS) and after percutaneous coronary
intervention (PCI).
Two antiplatelet medications used commonly in these
populations are aspirin and clopidogrel. Platelet function
testing has documented substantial variability in the phar-
macodynamic response to both medications; however, the
prevalence and clinical impact of this variability remain
largely unknown.
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Several methods for assessing platelet responsiveness to
clopidogrel or aspirin are available. Light-transmission
aggregometry (LTA) is the historical ‘‘gold standard’’ for
evaluation of the pharmacodynamic response to platelet-
directed medications. The major disadvantages are: (1)
increased processing time per sample because of the need
to generate platelet rich plasma, and (2) increased inter-
operator variability. The vasodilator-activated phospho-
protein (VASP) test measures the intracellular platelet
response to medications inhibiting the platelet P2Y12
receptor. Like LTA, it is a time-consuming, laboratory-
based test that is technically demanding.
Newer point-of-care whole blood aggregation tests are
now available. Of these, the VerifyNow (Accumetric,
Inc., San, Diego, CA) and Multiplate (Verum Diagnosti-
ca, Munich, Germany) tests have undergone extensive
clinical validation. In the Do Platelet Function Assays
Predict Clinical Outcomes in Clopidogrel Pretreated
Patients Undergoing Elective PCI (POPULAR) study
comparing the predictive value of different platelet func-
tion tests for thrombotic and bleeding outcomes following
elective PCI, the VerifyNow test demonstrated a c-statistic
comparable to LTA in its ability to discriminate future
thrombotic outcomes. Similarly, the Multiplate test per-
formed well in a large German multicenter study investi-
gating the relationship between its adenosine diphosphate
(ADP) test and thrombotic outcomes after PCI.
However, the ability of existing platelet function tests to
predict bleeding outcomes is more limited. To date, the
association between platelet function measurements and
future bleeding outcomes has been equivocal—this
remains a key limitation of platelet function testing.
Another key limitation of currently available platelet
function tests is their inability to reliably report on the
composite effect of multiple antiplatelet agents acting via
different pathways. A further unresolved question is the
ability of a platelet function testing-guided strategy to
improve clinical outcomes. Although the recently com-
pleted Gauging Responsiveness with a VerifyNow
Assay—Impact on Thrombosis and Safety (GRAVITAS)
trial did not demonstrate an improvement in clinical out-
comes with double-dose clopidogrel in patients with
clopidogrel hypo-responsiveness identified using the Ver-
ifyNow system, other ongoing trials employing more
potent P2Y12 inhibitors will provide greater clarity on the
clinical utility of platelet function testing.
Proton-pump inhibitor (PPI)–clopidogrel interactions:
reality or myth?
In patients with ACS, current clinical practice guidelines
recommend the use of dual antiplatelet therapy with aspirin
and P2Y12 inhibition. Aspirin, particularly at higher doses,
leads not only to platelet inhibition by the effect on
thromboxane A2 but also to effects on the gastric mucosa
through the inhibition of prostacyclin. This results in an
increased risk of peptic ulcer and gastric bleeding. Addition
of clopidogrel to aspirin further increases the risk of
adverse gastric bleeding events. To reduce this risk, treat-
ment with proton-pump inhibitors (PPI) is routinely used in
patients with previous peptic ulcer and often in patients
with risk factors for gastric bleeding such as acute care. In
fact, both clopidogrel and PPIs are among the most fre-
quently prescribed pharmacological agents worldwide.
The most important mechanism for a poor response to
clopidogrel is variable generation of the active metabolite.
Approximately 85% of a clopidogrel dose is hydrolysed by
esterases to an inactive metabolite. The remaining clopi-
dogrel is available to be converted to the active metabolite
in a process requiring two sequential cytochrome P450
(CYP)-dependent steps with CYP2C19 in both steps. A
genetically determined reduced function allele of
CYP2C19 slows clopidogrel metabolism, which leads to
lower levels of the clopidogrel active metabolite and a
lower pharmacodynamic platelet inhibitory effect.
Because some PPIs are known to be strong inhibitors of
CYP2C19 activity, it is reasonable to believe that PPI may
reduce the clinical response to clopidogrel. Controversy
remains over whether this treatment interaction is clinically
meaningful.
In November 2009, the U.S. Food and Drug Adminis-
tration (FDA) issued a warning that concomitant use of
omeprazole and clopidogrel should be avoided and that
other drugs that reduce stomach acid do not interfere with
the anti-clotting activity of clopidogrel. The European
Medicines Agency (EMEA) extended the warning to dis-
courage concomitant use of all PPIs unless absolutely
necessary. These recommendations were based on phar-
macokinetic/pharmacodynamic and observational studies.
Well-performed studies have shown that the mean plasma
concentration of the clopidogrel active metabolite is lower
in patients treated with omeprazole in combination with
clopidogrel than in patients treated with clopidogrel alone,
also with a 600-mg loading and 150-mg maintenance dose.
Pharmacodynamic studies have confirmed the reduction of
platelet reactivity.
Whether treatment with PPIs affects cardiovascular
outcome in patients receiving clopidogrel has been unclear.
Several small observational studies showed a significant
association between PPI use and cardiovascular risk,
whereas propensity-matched studies and substudies of
large randomized trials such as the Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition with Prasugrel-Thrombolysis in Myo-
cardial Infarction (TRITON-TIMI) 38 and the Platelet
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Inhibition and Patient Outcomes (PLATO) study revealed
no association. A recently performed meta-analysis
including 159,138 patients from 25 studies found an
association of PPIs with reduction in gastric bleeding
events and a higher risk of stent thrombosis but no asso-
ciation with the risk of death. One randomized trial, the
Clopidogrel and the Optimization of Gastrointestinal
Events Trial (COGENT), studied the effect of omeprazole
versus placebo in patients treated with dual antiplatelet
therapy. Although the trial was stopped prematurely for
financial reasons, 3,637 patients were enrolled. The trial
showed a 66% relative reduction in gastrointestinal events
but no effect of omeprazole on cardiovascular events.
In summary, the totality of data suggests that a phar-
macokinetic and pharmacogenetic clopidogrel–PPI inter-
action via CYP2C19 is real but that concomitant use of
PPIs has minimal or no clinical consequence in low–
medium-risk patients on long-term treatment. A small but
clinically meaningful interaction with PPI in ACS patients
at high ischemic risk in the acute settings cannot be
excluded. Treatment with other potent P2Y12 receptor
inhibitors, such as prasugrel and ticagrelor, is not associ-
ated with an interaction with PPIs and could be considered
in patients at high risk for ischemic events. In patients at
risk for peptic ulcer, treatment with effective gastric pro-
tection, including PPIs, should not be withheld.
New antiplatelet agents under development
Current management of ACS includes risk stratification by
clinical findings and the use of electrocardiographic and
biochemical markers. It is recommended that all patients
with an established diagnosis of ACS receive immediate
antithrombotic treatment with dual platelet inhibition
(aspirin and a P2Y12 inhibitor) plus intravenous or subcu-
taneous anticoagulation. In addition, patients should also
receive beta-blockers, statins, and, frequently, angiotensin-
converting enzyme (ACE) inhibitors. The majority of
patients hospitalized for ACS are rapidly admitted to a
catheterization laboratory for identification of the culprit
lesion, followed by balloon dilatation and stenting if fea-
sible. At discharge, it is generally recommended that
patients receive long-term secondary prevention with a
combination of aspirin, beta-blockers, statins, ACE inhib-
itors, and P2Y12 inhibitors for at least 1 year. However,
despite these measures, there is still a 10% risk of death,
reinfarction, or stroke during the year following discharge.
The magnitude of this risk varies among patient popula-
tions, with the highest risk in older patients and those with
diabetes mellitus, previous myocardial infarction (MI),
cardiac or renal dysfunction, manifestations of atheroscle-
rotic disease, or multi-vessel coronary artery disease
(CAD). If current therapeutic approaches for ACS are to be
improved, greater focus will be needed on these high-risk
groups.
New therapies currently under development aim to
prevent further progression of thrombosis and atheroscle-
rosis and to correct underlying metabolic disturbances
(e.g., diabetes and dyslipidemia). The primary challenge in
preventing and managing ACS, both now and in the future,
will be to tailor treatments for each patient, taking into
consideration patient characteristics, comorbidities,
underlying short- and long-term risk factors, and expected
individual responses to different medications. These
ambitions will likely place a substantial burden on global
health care resources and may ultimately require prioriti-
zation among several treatment alternatives.
Platelet inhibition has been a mainstay in the prevention
of MI and death in patients with ACS for approximately
20 years. Aspirin therapy yields consistent inhibition of
platelet thromboxane A2 release. However, inhibiting this
pathway only modestly attenuates platelet activation
without any influence on ADP-induced platelet activation.
Aspirin treatment reduces the relative risk of MI and death
by 30–50% compared with placebo in patients with ACS.
However, aspirin alone has no convincing effect on pre-
vention of stent thrombosis. Therefore, other pathways
need to be inhibited in the highly prothrombotic environ-
ment of ACS. The P2Y12 receptor plays a major role in the
ADP-mediated amplification of platelet response regardless
of the stimulus. Clopidogrel and prasugrel are thienopyri-
dine pro-drugs acting on this receptor by almost identical
active metabolites that irreversibly bind to the receptor.
Slow and variable active metabolite generation leads to
clopidogrel having a slow onset of action and wide inter-
individual variability in pharmacodynamic response.
However, as shown in the Clopidogrel in Unstable Angina
to Prevent Recurrent Events (CURE) trial, compared with
aspirin alone, clopidogrel provided a relative 20% reduc-
tion in death, MI, or stroke at a median of 9 months of
treatment. Despite variability in platelet responsiveness,
the Clopidogrel Optimal Loading Dose Usage to Reduce
Recurrent Events/Optimal Antiplatelet Strategy for Inter-
ventions (CURRENT/OASIS) 7 trial—a 2 9 2 factorial
randomized comparison of standard-dose (300 mg load/
75 mg daily) versus higher-dose (600 mg load/150 mg
daily for 6 days, then 75 mg daily) clopidogrel and lower-
dose (75–81 mg) versus higher-dose (325 mg) aspirin
treatment—failed to show superiority for the higher-dose
clopidogrel regimen. However, in a subgroup analysis of
PCI-treated patients, there was a substantial reduction in
stent thrombosis in patients treated with the higher-dose
clopidogrel regimen.
Generation of the active metabolite of prasugrel is more
efficient than for clopidogrel, resulting in more rapid onset
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of action, more pronounced platelet inhibition, and no
clinically important variability in response. In the setting of
these pharmacokinetic and pharmacodynamic features,
prasugrel treatment resulted in a 20% reduction in death,
MI, or stroke and a halving of the risk of stent thrombosis
compared with clopidogrel in the TRITON-TIMI 38 trial of
patients undergoing a planned PCI procedure. However,
both the addition of clopidogrel to aspirin and the use of
prasugrel instead of clopidogrel were associated with sig-
nificant increases in major bleeding in CURE and TRI-
TON-TIMI 38, respectively.
Ticagrelor, the first reversibly binding oral P2Y12
receptor antagonist, does not require metabolic activation,
has a rapid onset of action, and can disassociate from the
receptor, permitting restoration of platelet function without
the need for production of new platelets. In pharmacody-
namic studies, ticagrelor demonstrated greater, more rapid,
and more consistent ADP-induced platelet inhibition
compared with clopidogrel and more rapid offset of action
following cessation of therapy. In the PLATO study,
18,624 patients with ACS were randomized within 24 h
after symptom onset to ticagrelor versus clopidogrel. The
results showed a 16% relative reduction of the composite
of cardiovascular death, MI, or stroke, a 22% reduction in
total mortality, and a 33% reduction in definite stent
thrombosis. Ticagrelor was not associated with an increase
in overall bleeding, but, during long-term treatment, there
was more non-procedural bleeding with ticagrelor.
Currently, elinogrel, a reversibly binding competitive
P2Y12 receptor antagonist for both intravenous and oral
administration, is under evaluation. In a recently presented
phase II trial (Novel Intravenous and Oral P2Y12 Inhibitor
in Non-Urgent PCI [INNOVATE-PCI]), elinogrel was
associated with a slight dose-related increase in total
bleeding without a clear signal for reduction in ischemic
events compared with clopidogrel.
Other targets for platelet inhibition are also under
investigation (e.g., the protease-activated receptor 1 [PAR-
1]). Preclinical and phase II studies suggest that consistent
and high levels of PAR-1 inhibition may have a beneficial
antithrombotic effect with minimal increase in bleeding.
Phase III studies of the selective PAR-1 inhibitor, vora-
paxar, are currently underway, both in ACS and chronic
CAD.
In conclusion, several new alternatives providing more
rapid and consistent platelet inhibition than clopidogrel are
currently being explored for routine treatment of patients
with ACS. These new treatments seem to provide addi-
tional benefits to the patients without unacceptable
increases in the risk of bleeding if used appropriately.
Within the next few years, even more treatment alterna-
tives might be available to further improve outcomes of the
large patient population with ACS.
Novel parenteral anticoagulants
Despite its limitations, unfractionated heparin (UFH)
remains a commonly used parenteral anticoagulant in
clinical practice. The major limitations of UFH include
an unpredictable pharmacodynamic response, associated
off-target effects, and the need for pharmacodynamic
monitoring. Lack of pharmacologic specificity is another
limitation. As such, the scientific community has moved
toward using novel anticoagulants that target singular
proteases within the coagulation system.
Bivalirudin, a direct thrombin inhibitor with a short
circulating half-life, has recently shown good clinical
efficacy with less bleeding compared with either UFH or
LMWH. The synthetic pentasaccharide, fondaparinux, is a
specific, indirect inhibitor of factor Xa. Despite, the con-
venience of a once-a-day subcutaneous injection for the
management of patients with ACS, the need for supple-
mental UFH during transition to the catheterization labo-
ratory limits its wider adoption in clinical practice.
Concerns also remain over the propensity for equipment-
associated thrombosis, as well as the absence of a reliable
antidote to reverse its anticoagulant effect. Another factor
Xa inhibitor, otamixaban, has demonstrated early safety as
a parenteral anticoagulant in the catheterization laboratory;
in the phase II Otamixaban in Comparison to Heparin in
Subjects Undergoing Non-Urgent Percutaneous Coronary
Intervention (SEPIA-PCI) trial, equipment-associated
thrombosis occurred at a similar rate in both otamixaban
and UFH-treated patients.
In response to existing limitations of approved paren-
teral anticoagulants, REG1 was designed to achieve rapid
inhibition of factor IXa with active, antidote-mediated
reversibility. This drug-antidote construct is now under-
going late phase II testing in patients with ACS.
Vitamin K antagonists
The vitamin K antagonists (VKAs) have been the only
anticoagulants available for oral use since their first
administration to a patient more than 50 years ago. The
mechanism of action of this drug class is complex; they
achieve their anticoagulant effect by inducing the synthesis
of dysfunctional forms of factors II, VII, IX, and X. The
target of VKAs is the enzyme vitamin K epoxide reductase
(VKOR). Single nucleotide polymorphisms in the gene that
codes for this enzyme (as well as single-nucleotide poly-
morphisms [SNPs] in the genes that encode CYP2C9) can
render the patient more (or, in some cases, less) sensitive to
warfarin; thus, common genetic variations, along with
factors such as sex, age, and weight, lead to significant (and
sometimes unpredictable) inter-individual variability in the
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dose required to achieve the targeted anticoagulant effect.
Even patients whose dose has been determined through
titration and adjustment can experience clinically relevant
sudden changes in their anticoagulant effect because of
interactions with diet (mostly due to variation in vitamin K
intake) or other medications (especially drugs that interact
with the cytochrome P450 system). These features, along
with the narrow therapeutic index, slow onset, and long
pharmacodynamic half-life characteristic of VKAs, have
created challenges for clinicians and patients alike.
Despite the undesirable attributes of VKAs, they have
proven to be extremely effective in the prevention of AF-
related stroke, recurrent venous thromboembolism (VTE),
and other unwanted clinical events. Recently, the inconve-
nience of VKAs has been reduced by the opportunity for
patient self-testing, but self-testing does not necessarily make
VKAs safer or more effective than they are in the context of a
dedicated system of anticoagulation management. Indeed,
the safety of VKAs has improved with the advent of dedicated
anticoagulation management services and the application of
evidence-based strategies to reverse the VKA anticoagulant
effect in bleeding patients. Going forward, it is likely that
VKA use will decrease, but not disappear, once new oral
anticoagulant agents become available.
ACS with ST-segment elevation: guidelines perspective
on antithrombotic therapy
Many anticoagulants and antiplatelet agents are now
available for the treatment of ACS patients. In patients with
ST-segment elevation MI (STEMI) undergoing primary
PCI, clopidogrel and UFH or bivalirudin (a direct anti-
thrombin agent) are the most frequently used agents. For
patients treated with lytic therapy, UFH, enoxaparin, and
fondaparinux (with streptokinase only) are used as anti-
coagulant co-therapy. Clopidogrel is also given routinely
with lytic agents to patients under age 75 years. No reliable
data are available in patients aged [75 years.
Clopidogrel is widely used as an adjunctive therapy for
primary PCI and has also been shown to be beneficial in
patients treated with fibrinolytic therapy (Clopidogrel as
Adjunctive Reperfusion Therapy [CLARITY] study;
Clopidogrel and Metoprolol in Myocardial Infarction Trial
[COMMIT/CCS-2]). However, its limitations—particu-
larly slow onset of action, variability in response, and
irreversible binding to the P2Y12 receptor—create chal-
lenges for STEMI care. Prasugrel, approved for use in
Europe in 2009 and in the U.S. in 2009, is a third-gener-
ation thienopyridine and has a similar mechanism of action
to clopidogrel but superior pharmacokinetic characteristics.
The greater efficacy of prasugrel over clopidogrel in the
TRITON-TIMI 38 trial was particularly evident in patients
with STEMI, all of whom underwent primary PCI. How-
ever, prasugrel was associated with an increased risk of
major bleeding, although in the STEMI population, there
was no increase in life-threatening bleeding compared with
clopidogrel.
Several novel antiplatelet therapies are currently in
clinical development or have only recently been approved.
The PLATO study demonstrated that ticagrelor reduced the
incidence of death, MI, or stroke by 16% and of cardio-
vascular death by 22% compared with clopidogrel in
STEMI patients. With ticagrelor, there was an increased
risk of non-coronary artery bypass graft (CABG) bleeding
complications. Also, cangrelor is an intravenous, fast,
direct-acting, and reversible P2Y12 inhibitor. No significant
differences with clopidogrel could be demonstrated in ACS
patients in the Cangrelor versus Standard Therapy to
Achieve Optimal Management of Platelet Inhibition
(CHAMPION) PCI trial.
It is likely that prasugrel and ticagrelor will be recom-
mended in the guidelines for STEMI patients undergoing
primary PCI. Because these agents have not been tested
prospectively with lytic agents, clopidogrel will remain the
recommended ADP antagonist with lytic therapy.
Obviously, there is no role for new oral anticoagulants
such as rivaroxaban and apixaban in the acute reperfusion
phase of STEMI. Whether these agents may prevent
recurrent ischemic events afterwards is unknown.
Antithrombotic therapy in ACS
with non-ST-segment elevation
There are three antithrombotic agents to choose from: en-
oxaparin, fondaparinux, and bivalirudin. All have been
shown to be superior to UFH. However, there are a number
of considerations in choosing an antithrombotic agent for
non-ST-segment elevation ACS. These include ischemic
risk, bleeding risk, whether an invasive or conservative
strategy will be employed, time to catheterization (\12 h vs.
[12 h), whether drugs will be switched, whether the patient
is aged\75 or C75 years, and the patient’s renal function.
Major bleeding is strongly associated with subsequent
mortality and ischemic events and, many believe, is at least
as important as reinfarction. Most bleeding complications
are iatrogenic, attributable to femoral artery access for PCI,
and related to the use of potent antiplatelet and anti-
thrombin medications. The incidence of bleeding is affec-
ted by the choice of anticoagulant and overdosing.
Enoxaparin has been shown in trials of over 22,000
patients to reduce death and MI by 20% and to have similar
outcomes as compared with UFH when a conservative
strategy is employed, but its use is associated with a modest
increase in bleeding when an invasive strategy is employed.
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There is also a large clinical experience for bivalirudin
in non-ST-segment elevation ACS. Over 20,000 patients
have been randomized in trials showing that major bleed-
ing is reduced by about 50% with no increase in ischemia
compared with UFH.
Crossover of antithrombotics
The patients in the Superior Yield of the New Strategy of
Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa
Inhibitors (SYNERGY) trial who crossed over between
UFH and enoxaparin had an increase in bleeding compli-
cations. Crossover occurred at various times through the
study period, at times in response to clinical or clinician
perception. In a secondary analysis from this study, results
indicated a significant association between crossover from
enoxaparin to UFH and TIMI bleeding but not in the other
direction, and no crossover association was found in death
or MI.
Switching from UFH or enoxaparin to bivalirudin in the
Acute Catheterization and Urgent Intervention Triage
Strategy (ACUITY) trial was not associated with an
increased risk for ischemic events. Furthermore, switching
to bivalirudin provided patients with a 50% reduction in
bleeding.
Fondaparinux is an indirect factor Xa inhibitor tested
against enoxaparin in the Organization to Assess Strategies
in Acute Ischemic Syndromes (OASIS)-5 trial. The ische-
mia rate was similar to UFH, but severe bleeding compli-
cations were significantly reduced with fondaparinux, and
long-term mortality and stroke rates were also reduced.
Because of a higher rate of catheter thrombosis when
fondaparinux alone is used, UFH (85 l/kg) should be
added for patients undergoing PCI.
If there is a very high risk of ischemia, bivalirudin is
recommended, or UFH with a IIb/IIIa antagonist added if
there is angiographic thrombosis or poor TIMI flow. If
there is a low-to-high risk of ischemia, all four agents
(fondaparinux, LMWH, UFH, and bivalirudin) are good
choices. Bivalirudin is an attractive option if there is an
increased risk of bleeding and an early invasive strategy is
planned. Fondaparinux is a good option if a conservative
strategy is planned.
A number of different anticoagulant strategies can be
appropriately selected based on individual risk stratifica-
tion for ischemia and bleeding.
Biomarkers of thrombosis: where do we stand in 2010?
From a clinical perspective, biomarkers serve three main
purposes: to diagnose or exclude a disease diagnosis; to
provide information about prognosis or to risk stratify; and,
most elusively, to guide treatment decisions. Pulmonary
embolism (PE) and acute MI are two acute thrombotic
disease entities, often presenting with similar symptoms,
for which clinically useful biomarkers of thrombosis have
evolved across each of these three domains.
Pulmonary embolism is first classified as high or inter-
mediate/low risk based on hemodynamic and respiratory
status. For those who are stable (i.e., intermediate/low
risk), the biomarker, D-dimer, is used to exclude the
diagnosis of PE and to guide further imaging and/or
treatment. Given its exquisite sensitivity, despite low
specificity, its negative predictive value is very high, such
that further work-up with imaging or treatment is not
necessary if the D-dimer concentration is low.
Troponin remains the gold standard for establishing a
diagnosis of MI in the setting of clinical symptoms of
ischemia. Troponin assays are more sensitive and more
specific for myocardial injury than creatine kinase
(CK)-MB. However, the increasing clinical availability of
high-sensitivity troponin assays that can detect circulating
troponin at levels well below the 99th percentile of a
normal reference population and can also achieve 10%
coefficient of variation (CV) at the 99th percentile is
challenging the diagnostic utility of troponin testing for
diagnosis of MI. However, the increased sensitivity of
these assays is offset by reduced clinical specificity,
resulting in low positive predictive value. For example, up
to 70% of patients with heart failure, which often co-exists
with coronary disease, may present with elevated troponin
by high-sensitivity assays. The parameters for diagnostic
use of these assays are still being discussed. However,
these assays may be particularly useful in early diagnosis/
triage in the emergency room, where elevations above the
99th percentile in MI patients are detectable much earlier
than with standard assays. Given these challenges,
heightened awareness of the relationship of pre-test prob-
ability with the occurrence of false-positive (and false-
negative) diagnoses will be needed.
In the meantime, systematic efforts to increase the
accuracy of physicians’ clinical assessments of risk in
patients with suspected ACS must be undertaken. In a
study from the Canadian ACS 2 Registry, despite the
availability of the 12-lead electrocardiogram (ECG) and
results of assays for markers of myocardial necrosis, there
was little relationship between physician-estimated risk
category and that determined from available risk scores,
with wide variability in these risk scores within the phy-
sician-estimated category. A better alignment between
physician-estimated risk and systematically determined
risk is critical as this study also showed that physicians,
overall, treat patients whom they judge as being at higher
risk more aggressively with both coronary procedures and
medications.
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Even with a systematic approach to risk stratification,
novel or existing biomarkers may be useful in refining
prognosis or guiding treatment selection. Many biomarkers
of thrombosis and inflammation have been identified, but
rarely have studies considered more than a few biomarkers
simultaneously, and few have made the translation from
biomarker of risk to biomarker for stratified application of
treatments. Troponin testing is the cardiovascular bio-
marker that best exemplifies this feature. In studies mostly
done with older assays, troponin identified high-risk pop-
ulations that were most likely to benefit from glycoprotein
(GP) IIb/IIIa inhibitors, LMWH, and a strategy of early
angiography in patients presenting with non-ST-segment
elevation ACS. Whether this will be true as high-sensitivity
troponin assays become available, particularly for levels
below the 99th percentile of current assays, remains to be
seen.
The role of high-sensitivity C-reactive protein (hsCRP)
in guiding therapy with statins recently has come under
scrutiny. Although the Justification for the Use of Statins in
Prevention: an Intervention Trial Evaluating Rosuvastatin
(JUPITER) showed that patients with normal low-density
lipoprotein cholesterol (LDL-C) who had an hsCRP
level [ 2 mg/dl benefitted from treatment with rosuvasta-
tin, there was no arm with similar LDL-C levels but
hsCRP \ 2 mg/dl. Thus, this trial cannot be used to argue
that hsCRP should be used to guide statin treatment in
primary prevention patients. Additionally, a recent cost-
effectiveness analysis suggested that, assuming long-term
safety of statins, availability of low-cost generic agents,
and similar efficacy of statins in low-to-intermediate risk
patients, treating men with statins without screening hsCRP
would be cost-effective down to 50 years. At 70 years,
using hsCRP to guide therapy would be cost-effective in
both men and women; in both men and women, the lower
bounds of age for primary prevention without hsCRP
guidance rose with increasing numbers of cardiovascular
risk factors.
As an example of the increasing interface of genetics
with clinical care, there has been much interest in the use of
genetic testing for the CYP2C19 mutation to guide clopi-
dogrel therapy. However, despite associations of the
mutation with outcome and demonstrated pharmacody-
namic and pharmacokinetic variability with clopidogrel
treatment according to carrier status, studies to date have
not demonstrated that testing for this genetic mutation is
useful in guiding treatment. A large randomized clinical
trial, GRAVITAS, evaluated whether tailored clopidogrel
dosing according to phenotypic platelet responsiveness
measured prior to discharge after drug-eluting stent
implantation would reduce thrombotic complications of
stent implantation. Its results were presented at the 2010
Scientific Sessions of the American Heart Association
(AHA) in Chicago and showed no benefit on cardiovas-
cular outcomes or stent thrombosis with a double dose of
clopidogrel in patients receiving drug-eluting stents with
high residual platelet activity on the regular clopidogrel
dose. These results are not yet published.
Thus, in 2010, it is increasingly evident that global risk
assessment is needed to help clinicians align treatment with
diagnosis and risk. Biomarkers play an important role in
this process. However, rapid advances in assay technology
and the increasing availability of new biomarkers gener-
ated from genomic discovery and applications of genetic
testing create challenges that must be considered. Novel
biomarkers must be systematic and rigorously evaluated,
and their practical clinical utility must be demonstrated
before they become part of a routine risk assessment
strategy.
Measuring quality in ACS: where does
antithrombotic therapy fit?
Quality of care has been defined as the ‘‘degree to which
health care services increase the likelihood of desired
health outcomes and are consistent with current profes-
sional knowledge.’’ Simply put, this asks: Are we doing the
right things (practicing evidence-based care); are we doing
the right things right (delivering this care in a safe, skilled
manner); and are our patients better off for it (are their
outcomes improved)? When viewed in this manner, con-
temporary treatment of patients with ACS is challenged.
Studies have consistently demonstrated an under-utilization
of evidence-based therapies, as well as failure to provide
such care in a safe and timely fashion. And while care is
improving over time, consistent gaps remain. For example,
2010 data from the ACTION Registry-Get With the
Guidelines (GWTG)TM found that between 15 and 20% of
eligible ACS patients fail to receive dual antiplatelet
therapy acutely and at hospital discharge.
The standard application of evidence-based therapies,
however, neglects to consider that these treatments ideally
should be ‘‘personalized’’ for the individual patient. Anti-
thrombotic therapies in ACS care effectively prevent
recurrent ischemic events or, alternatively, cause iatrogenic
bleeding. The balance between the benefits and risks is
influenced by three domains. The first domain relates to
features of the drug itself, including drug absorption,
activation, potency, clearance, and interaction with other
drugs. Patient factors represent a second domain influenc-
ing safety and efficacy of antithrombotic therapies in ACS,
including such factors as patient age, sex, renal function,
and presence of diabetes. These clinical features influence
the baseline odds for recurrent ischemic events but also can
affect the safety of antithrombotic therapy, either through
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changing the drug’s pharmacokinetic and dynamic prop-
erties or increasing the patient’s underlying disposition to
bleed (i.e., peptic ulcer disease).
Provider and system factors also influence the quality of
care and subsequent outcomes in ACS. Studies have found
that a number of patients in the United States receive the
wrong dose of antithrombotic therapies. Combined, up to
20% of all bleeds in the United States are estimated to be
caused by excessive antithrombotic therapies. The reasons
for excessive drug dosing often relate to a failure to indi-
vidualize dose based on body weight, age, or renal
function.
While there are challenges to the effective and safe use
of antithrombotic therapies in ACS, the world is changing,
and efforts to improve the quality of ACS care delivered
around the world abound. In particular, giving clinicians
feedback on their care practices relative to those of their
peers has been shown consistently to improve ACS quality
of care. Moving forward, this follow-up and feedback
regarding ACS practices must extend to consider longitu-
dinal care and outcomes. For example, studies have con-
sistently demonstrated that patients who discontinue dual
antiplatelet therapy early after receiving a stent are at high
risk for subsequent cardiac events. Importantly, patient
compliance appears modifiable via patient education.
Those who understand the reasons for their medications
and the need for continued use have higher rates of
compliance.
In the future, both providers and patients will have
increasing access to electronic tools to facilitate better ACS
care. These include electronic order entry systems that will
support wiser drug choices and prevent medical errors
related to drug dosing. We will also see the evolution of
community systems of care that will encourage appropriate
triage of ACS patients to support more timely ACS care.
Finally, we will see the evolution of patient health records
that will support a new collaborative model of care
between patients and their caregivers.
Antiphospholipid syndrome
Antiphospholipid syndrome is widely recognized but
incompletely understood. There are five areas worthy of
consideration: pathophysiology, epidemiology, clinical
manifestations, diagnosis, and management. The patho-
physiology of antiphospholipid syndrome involves pro-
duction of IgG antibodies against beta 2-glycoprotein I on
the surface of vascular endothelial cells. The antibodies
cause expression of adhesion molecules and up-regulation
of tissue factor production. In addition, they produce up-
regulation of tissue factor within monocytes, expression of
GP IIb/IIIa receptors on platelets, and increased
thromboxane A2 synthesis. The interaction of antibodies
with coagulation regulatory proteins such as activated
protein C in combination with complement activation and
inflammation establishes a highly prothrombotic state. The
available evidence suggests that an existing thrombophilia
in antiphospholipid syndrome can be exaggerated acutely
as part of a putative ‘‘second hit’’ phenomenon following
trauma, infection, and other conditions in which a pro-
thrombotic environment rapidly develops.
Antiphospholipid antibodies are detected in 20% of
patients with an ischemic stroke before age 50 years, 20%
of patients with VTE, 10–15% of women with recurring
miscarriages, and 20% of women with a diagnosis of pre-
eclampsia. The most common clinical manifestations of
antiphospholipid syndrome, occurring in [20% of indi-
viduals, include VTE, thrombocytopenia, miscarriage or
fetal loss, ischemic stroke or transient ischemic attack,
migraine headache, and livedo reticularis. Less common
clinical manifestations, occurring in 10–20% of individuals,
include heart valve abnormalities, hemolytic anemia, and
accelerated CAD. Unusual clinical manifestations, occur-
ring in \10% of individuals, include seizures, vascular
dementia, retinal artery or vein thrombosis, pulmonary
hypertension, skin ulcers with digital gangrene, osteone-
crosis, renal insufficiency, and mesenteric ischemia.
The diagnosis of antiphospholipid syndrome is sup-
ported by clinical criteria, including vascular thrombosis
involving one or more episodes of arterial, venous, or
small-vessel thrombosis in any tissue or organ. Thrombosis
should be present without substantial evidence of inflam-
mation within the vessel wall. A diagnosis of anti-
phospholipid syndrome in the context of pregnancy is
supported by at least one of the following criteria: one or
more unexplained deaths of a morphologically healthy
fetus at or beyond the 10th week of gestation; one or more
premature births of a morphologically healthy new born
before the 34th week of gestation either because of
eclampsia or severe preeclampsia; or at least three unex-
plained consecutive spontaneous abortions before the 10th
week of gestation, with anatomical or chromosomal
abnormalities having been excluded.
The laboratory diagnosis of antiphospholipid syndrome
includes the following: detection of a lupus anticoagulant
on two or more occasions at least 12 weeks apart; anti-
cardiolipin antibody of IgG or IgM subtype, or both in
serum or plasma, present in medium or high titers on at
least two or more occasions at least 12 weeks apart mea-
sured with a standardized ELISA; or anti-beta 2 GP1
antibody of IgG or IgM subtype, or both in serum or
plasma, at medium or high titers on at least two or more
occasions at least 12 weeks apart.
The management of patients with antiphospholipid
syndrome includes a strategy of primary prophylaxis,
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where patients with systemic lupus erythematosus and a
circulating lupus anticoagulant or persistently positive
anticardiolipin antibody titer would receive hydroxychlo-
roquine either alone or in combination with low-dose
aspirin. Patients with obstetric antiphospholipid syndrome
are traditionally treated with low-dose aspirin, while
asymptomatic carriers of antiphospholipid antibodies do
not typically require therapy. However, it is important to
emphasize that all patients with antiphospholipid antibod-
ies likely benefit from strict control of vascular risk factors
and should receive adequate thromboprophylaxis in high-
risk situations such as surgery, the post-partum period, and
during prolonged periods of immobilization. Management
of patients with antiphospholipid syndrome without pre-
vious thrombosis but recurring early (pre-embryonic or
embryonic) miscarriages should include either low-dose
aspirin alone or in combination with either UFH or
LMWH. Patients with antiphospholipid syndrome without
previous thrombosis but with prior fetal death at more than
10 weeks gestation or early delivery (\34 weeks gestation)
due to severe preeclampsia or placental insufficiency
should be treated with UFH or LMWH throughout
pregnancy.
Secondary prophylaxis of patients with antiphospholipid
syndrome and prior thrombosis typically includes indefinite
anticoagulation with warfarin, titrated to a target INR of
2.5 (range 2.0–3.0). There is a suggestion that patients with
a prior arterial thrombotic event should be targeted to a
higher INR (3.5; range 3.0–4.0) or warfarin titrated to a
target INR of 2.5 plus low-dose aspirin. The latter two
strategies have also been used for patients with recurring
events despite warfarin anticoagulation.
The potential use of newer-generation anticoagulants,
such as oral direct factor Xa or direct thrombin inhibitors,
will require further evaluation.
Venous thromboembolism prophylaxis in surgical
patients
Venous thromboembolism is the most preventable cause of
morbidity and mortality in postoperative settings; it is the
second most common medical complication, the third most
common source of excess health care resource utilization,
and the third most common cause of mortality in postop-
erative patients. Accordingly, pulmonary embolism is the
most common yet preventable cause of death.
Proximal vein VTE presents the highest risk for PE:
50% asymptomatic or ‘‘silent’’ PE and 25% of distal vein
VTE will extend to proximal veins within 1 week of pre-
sentation. Most postoperative cases of VTE are clinically
silent: 2–30% of in-hospital postoperative deaths are
attributable to PE.
Over 30 million operations are performed annually in
the United States, and the incidence of postoperative VTE
without prophylaxis is 10–20% for low-risk and up to 80%
in high-risk patients. The rates of fatal PE in the highest-
risk patients range from 0.5 to 30%, with length of hospital
stay of 5.4 days, excess mortality of 6.6%, and costs
reaching $25,000 more than compared with controls.
There were approximately 38 million discharges in the
United States in 2006: 7 million were surgical inpatients.
According to American College of Chest Physicians
(ACCP) Antithrombotic and Thrombolytic Guidelines risk
categories, 44% of these patients were at low risk for VTE;
15, 24, and 17% were at moderate, high, and very high risk,
respectively. Risk assessment strategy and systematic
computerized electronic alerts should be a combined
objective to increase the use of VTE prophylaxis and to
reduce the rates of symptomatic VTE among hospitalized
patients.
For prevention of this common problem, new evidence
is available to support novel anticoagulant therapy.
Rivaroxaban
Evidence for this oral, direct factor Xa inhibitor for
thromboprophylaxis was presented in the results from the
Regulation of Coagulation in Orthopedic Surgery to Pre-
vent Deep Venous Thrombosis and Pulmonary Embolism
(RECORD) 1, 2, 3, and 4 trials (Table 1). The RECORD 1
trial was designed to evaluate oral rivaroxaban compared
with subcutaneous enoxaparin for extended thrombopro-
phylaxis after total hip arthroplasty. The primary outcome
was total VTE: any deep vein thrombosis (DVT), non-fatal
PE, and all-cause mortality at 36 days (range 30–42);
secondary outcomes included major VTE: proximal DVT,
non-fatal PE, and VTE-related death. DVT included any,
proximal, distal, and symptomatic VTE.
In the RECORD 2 trial, extended thromboprophylaxis
with oral rivaroxaban versus short-term subcutaneous en-
oxaparin following total hip replacement was evaluated.
The main study question was whether extended-duration
prophylaxis was superior to short-duration prophylaxis. In
summary, RECORD 2 showed that extended-duration
prophylaxis was superior to short-duration prophylaxis and
that rivaroxaban provided an effective option for such a
strategy and had a good safety profile.
Finally, RECORD 3 and 4 evaluated thromboprophy-
laxis after total knee arthroplasty and found that rivarox-
aban (10 mg once a day for 10–14 days), given in a fixed,
once-daily dose regimen without coagulation monitoring,
was superior to enoxaparin (40 mg once a day for
10–14 days) in preventing venous thrombosis with similar
rates of bleeding.
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Apixaban
Apixaban, an oral, direct factor Xa inhibitor, was evaluated
for DVT prophylaxis after total knee replacement in a
phase II dose-ranging study. Aggregated apixaban doses
resulted in a 21% (P \ 0.02) reduction in VTE and all-
cause death compared with enoxaparin and a 53%
(P \ 0.01) reduction compared with warfarin. Major
bleeding event rates were low (0–3.3%) and comparable
across all apixaban arms and the enoxaparin and warfarin
groups. Similar results were shown in a dose-ranging trial
for the treatment of DVT.
The phase III, randomized, double-blind Apixaban Dose
Orally versus Anticoagulation with Enoxaparin
(ADVANCE)-1 trial compared the efficacy and safety of
2.5 mg oral apixaban twice daily to subcutaneous 30 mg
enoxaparin for the prevention of VTE after total knee
replacement in 3195 patients. The primary outcome rates in
each arm were similar (8.99% vs. 8.85%). The predeter-
mined non-inferiority end point was not met, but event
rates were comparable, and there was less clinically rele-
vant bleeding in the apixaban arm. There was no difference
between the two groups in serious adverse events.
The Apixaban Dose Orally versus Anticoagulation with
Enoxaparin (ADVANCE)-2 trial compared apixaban
(2.5 mg orally twice daily) with enoxaparin (40 mg sub-
cutaneously daily) for preventing VTE after total knee
replacement. The primary efficacy outcome (all VTE)
occurred in 15.1% of patients in the apixaban group and
24.4% in the enoxaparin group. A nonsignificant trend
toward less clinically relevant bleeding also favored apix-
aban (3.5 vs. 4.8%, P = 0.09).
The Apixaban Dose Orally versus Anticoagulation with
Enoxaparin (ADVANCE)-3 trial evaluated the efficacy and
safety of oral, twice-daily apixaban 2.5 mg compared with
subcutaneous enoxaparin 40 mg once daily in patients
undergoing elective total hip replacement surgery. In this
study, the primary efficacy end point occurred in 1.4% of
patients in the apixaban group and 3.9% of patients in the
enoxaparin group, demonstrating a statistically significant
relative risk reduction for apixaban of 64% (P \ 0.001 for
non-inferiority and superiority). The safety outcome of
major bleeding occurred in 0.8% of patients who received
apixaban and in 0.7% of patients who received enoxaparin
(P = 0.54). There was no difference between the two
groups in serious adverse events.
Dabigatran
In patients undergoing total hip replacement who were
enrolled in the Dabigatran Etexilate Compared with En-
oxaparin in Prevention of VTE Following Total Hip
Arthroplasty (RE-NOVATE) trial, both doses of the oral
direct thrombin inhibitor, dabigatran etexilate, given for a
median of 33 days were as effective as enoxaparin for the
prevention of VTE, with a similar safety profile. Further-
more, dabigatran etexilate proved to be non-inferior to
enoxaparin, when administered for the same duration, for
reducing the risk of total VTE and all-cause mortality after
total hip replacement. In patients undergoing total knee
replacement who were enrolled in the Thromboembolism
Prevention after Knee Surgery (RE-MODEL) trial, both
doses of the oral direct thrombin inhibitor dabigatran
etexilate, given for 6–10 days, were as effective as enox-
aparin for the prevention of VTE, with a similar safety
profile. Dabigatran etexilate proved to be non-inferior to
enoxaparin (40 mg daily started the night before surgery)
for the prevention of VTE after total knee replacement.
Should patients with cancer receive primary VTE
prophylaxis?
Patients with cancer are at high risk for VTE, which is the
cause of death in many patients with advanced malignancy.
The risk for developing VTE is highest during the first
3 months after diagnosis and depends on many factors,
including the use (and type) of chemotherapy as well as the
Table 1 Main efficacy outcomes of the RECORD trials
Trial Setting Enoxaparin
regimen
Rivaroxaban
regimen
DVT/PE/death
(%)
RRR
(%)
Symptomatic VTE
(%)
RRR
(%)
RECORD 1,
n = 4,541
Hip arthroplasty 40 mg qd, 35 d 10 mg qd, 35 d 3.7 vs. 1.1 70 0.5 vs. 0.3 NS
RECORD 2,
n = 2,509
Hip arthroplasty 40 mg qd,
10–14 d
10 mg qd, 31–39 d 9.3 vs. 2.0 79 1.2 vs. 0.2 80
RECORD 3,
n = 2,531
Knee
arthroplasty
40 mg qd,
10–14 d
10 mg qd, 10–14 d 18.9 vs. 9.6 49 2.0 vs. 0.7 66
RECORD 4,
n = 3,148
Knee
arthroplasty
30 mg bid,
10–14 d
10 mg qd, 10–14 d 10.1 vs. 6.9 32 1.2 vs. 0.7 NS
Bid twice daily; d days; NS not significant; qd daily; RRR relative risk reduction
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site and stage of the neoplasm. Recent randomized trials
have confirmed the hypothesis that anticoagulants, espe-
cially when administered in therapeutic doses, can reduce
the risk of VTE in at-risk cancer patients. Unfortunately,
the absolute risk reductions achieved in several of the trials
reported to date have been small and do not justify the
hazards and costs associated with a strategy of routine
prophylaxis in all patients. For example, the Prophylaxis of
Thromboembolic Events in Cancer Patients Receiving
Chemotherapy (PROTECHT) study enrolled 1,150 patients
with advanced lung, breast, or colon cancer (all were
receiving chemotherapy) and randomly assigned them to
either nadroparin (prophylactic dose) or placebo. Although
the proportion of patients experiencing the primary end
point was lower in the treatment group (2.1 vs. 3.9%,
P = 0.033), this small risk difference has not resulted in
the adoption of primary prevention strategies for these
populations. The PROTECHT results indicate that 55
patients would have to be treated with LMWH for 1 year to
prevent one thromboembolic event.
At least two trials that have recruited patients with
pancreatic cancer receiving gemcitabine (and that com-
pared therapeutic-dose LMWH to placebo) have demon-
strated more dramatic risk reductions for VTE but did not
clearly show a survival advantage and have yet to be
published in full manuscript form. Several groups have
now validated the risk prediction model of Khorana et al.—
a scoring system that has demonstrated that the risk of
developing VTE increases with a number of factors, such
as elevated white blood cell or platelet count, increased
body mass index, or decreased hemoglobin. However, the
absolute VTE risk level at which practicing oncologists and
their patients should consider primary prevention remains
unclear and may change if/when oral anticoagulants are
shown to be effective for this purpose. At this time, the
National Cancer Center Network guidelines do not rec-
ommend routine use of primary VTE prophylaxis in any
outpatient cancer population, except for patients with
multiple myeloma who are receiving lenalidomide and
dexamethasone.
Are there patients with PE who can be treated
out of hospital?
Pulmonary embolism is a common condition affecting
more than 1.5 million Americans yearly. It is a serious
disease that accounts for 10% of all in-hospital deaths and
is a major contributing factor in another 10% of deaths.
Despite these elevated death rates, PE might be a more
benign condition when associated with a lower thrombus
burden. In this case, mortality is extremely low, and
patients might be considered for outpatient therapy.
Therefore, risk stratification is of utmost importance when
considering therapy in PE.
Several risk stratification scores have been developed
and include variables such as age, clinical status at hospital
admission (heart rate, blood pressure, and respiratory rate),
presence of cancer, and hypoxemia (SatO2 \ 90%). The
commonly used Geneva risk score demonstrates good
discrimination for the prediction of death, major bleeding,
and recurrent VTE at 3 months. Patients stratified as low
risk (80% of total) have a 2.2% event rate, whereas high-
risk patients have increased risk of complications (26%).
Another famous score called PESI (Pulmonary Embolism
Severity Index) performs similarly for the prediction of the
same end points. More recently, echocardiographic data
and biomarker measurements, such as cardiac troponins
(cTnT and cTnI) and brain natriuretic peptide (BNP), have
been included in these scores. Biomarkers predict death
and other complications following PE with an odds ratio as
high as 17.9 according to some studies. They also improve
discrimination beyond clinical and echocardiographic
variables. In conclusion, patients admitted with PE are at
different risk. Currently available risk stratification scores
help predict complications and enable the choice of the
most suitable therapy for each patient. A study from the
Netherlands presented as a late-breaking session at the
American Society of Hematology annual meeting in
December of 2010 indicates that out-of-hospital therapy
may be reasonable in selected patients with PE.
Approaches for patients with venous thrombosis
in unusual sites
The vast majority of proven episodes of DVT occur in the
deep veins of the legs. When they occur in the proximal
veins, embolization may travel to the lungs, producing PE.
DVT and PE are often described as VTE and comprise a
leading cause of hospital-acquired morbidity and mortality.
Venous thrombosis may occur in any vein. Recently, the
frequency of DVT in non-leg veins has increased dramat-
ically due to the increased sensitivity of our radiologic
investigations. For example, improved resolution of
abdominal ultrasonography and contrast-enhanced com-
puted tomography (CT) scanning has led to a rapid increase
in the frequency of detection of splanchnic venous
thrombosis, oftentimes occurring in patients with minimal
or no referable symptoms who are undergoing evaluation
for unrelated medical indications. Cerebral vein thrombosis
is a potentially devastating form of thromboembolism that
is optimally detected with magnetic resonance venography
or direct angiography. Again, due to the increasing avail-
ability and resolution of these modalities, the frequency of
detection of these thrombi is increasing. Finally, DVT may
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occur in other vascular sites such as the renal veins, pelvic
veins, pulmonary veins, and in varicose veins located in
any vascular distribution.
Thrombophilia testing is widely available and grossly
overused. However, there appears to be a particular pre-
dilection for patients with selected forms of thrombophilia
to develop thrombosis in unusual sites. For example,
patients with paroxysmal nocturnal hemoglobinuria (PNH)
appear to be particularly prone to develop Budd-Chiari
syndrome, while patients with the JAK-2 mutation appear
prone to splanchnic vein thrombosis. A recent systematic
review demonstrated that almost one third of patients
presenting with splanchnic venous thrombosis had the
JAK-2 mutation, with many patients having a normal
complete blood cell count. The JAK-2 mutation (although
recently discovered) has traditionally been identified as
being characteristic of myeloproliferative disorders. The
mechanism by which this mutation predisposes a patient to
splanchnic venous thrombosis is unknown. Both the lupus
anticoagulant and anticardiolipin antibody are frequently
detected in patients presenting with unusual forms of
thrombosis, particularly at young ages. Detection of anti-
phospholipid antibodies, including both lupus anticoagu-
lant and anticardiolipin antibody, is important because
most experts would recommend extended-duration therapy
with an oral anticoagulant in patients with these antibodies.
There are no specific therapies for the JAK-2 mutation, and
patients appear to be treated effectively with oral antico-
agulants. Patients with PNH may be resistant to warfarin
administered to a traditional INR between 2 and 3; recent
studies have suggested a high rate of ‘‘warfarin failure.’’
Eculizumab is a recently approved medication that blocks
the terminal complement components and thus reduces
hemolysis in patients with PNH. Indirect evidence suggests
that this medication may also ameliorate the thrombotic
complications of this disorder.
More common thrombophilias, such as the prothrombin
gene mutation, appear to be particularly common in
patients with cerebral vein thrombosis.
Ovarian vein and other pelvic vein thrombosis appear to
be particularly common in the peripartum period. Renal vein
thrombosis is particularly common in patients with renal cell
carcinoma and may be more common in patients with
nephrotic syndrome. DVT of the upper extremity is partic-
ularly common in the setting of indwelling central venous
catheters and in athletes, presumably because of impinge-
ment on the veins leaving the arm during vigorous exercise.
Patients with unusual site thrombosis appear to respond
to anticoagulation, with similar recurrence rates as patients
with PE or thrombosis in the deep veins of the leg. Thus, a
rapid-acting parenteral anticoagulant should be adminis-
tered initially and overlapped with an oral VKA. This
therapy may need to be modified as a result of studies of
novel agents that may or may not require the initial course
of parental anticoagulants.
There is no evidence as to how patients with ‘‘asymp-
tomatic’’ clots should be treated. Most experts would treat
patients with thrombi discovered in the setting of cancer or
other high-risk situations. If there is reasonable evidence of
prior thrombosis, then it may be reasonable to not antico-
agulate. Patients who appear to be at high risk of compli-
cations, however, probably should be anticoagulated using
a rapid-acting, parenteral anticoagulant overlapped with an
oral VKA.
The duration of therapeutic anticoagulation has not been
studied in these patients. Most experts extend anticoagu-
lation because of a perception that recurrent disease could
be associated with catastrophic complications. However,
there is reasonable evidence that anticoagulants can be
safely discontinued in selected patients, particularly in
those with cerebral vein thrombosis.
In summary, DVT may occur in any vein. Thrombo-
philias appear to be particularly common in patients with
unusual site thrombosis. Recent attention has focused on
the JAK-2 mutation and PNH as causes of splanchnic and
hepatic vein thrombosis, respectively. Anticoagulant ther-
apy is indicated for all symptomatic patients. Optimal
therapy of patients with screening-detected clots is
unknown. In general, anticoagulant therapy is extended in
patients with unusual site thrombosis due to the potentially
catastrophic implications of recurrence.
Debate: VTE prophylaxis should be the default position
for hospitalized medical patients—for/against
Thromboprophylaxis: the case against
There is no question that selected patients admitted to the
hospital with medical disorders are at high risk of DVT and
PE, oftentimes described as VTE. However, recommen-
dations for the use of VTE prophylaxis have tended to err
on the side of suggesting prophylaxis for most patients,
despite a singular lack of evidence to support this recom-
mendation. The ACCP guidelines recommend strongly that
anticoagulant prophylaxis be provided to patients identified
at high risk of VTE. Such patients include those with an
extended duration of immobilization, congestive heart
failure, serious thrombophilias, or those with more than
one risk factor.
The case that VTE prophylaxis is not required in all
patients is made simply. Patients with active bleeding or
those perceived to be at very high risk of bleeding should
not receive pharmacologic prophylaxis, thus establishing
that there is a small but important subgroup of patients in
whom prophylaxis is contraindicated. The bigger question
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is whether VTE prophylaxis should be provided to low-to-
moderate-risk patients.
Prophylaxis may be mechanical or pharmacologic.
Mechanical prophylaxis can be active or passive. Passive
mechanical prophylaxis, most commonly manifest as grad-
uated compression stockings (GCS), are probably effective
for the prevention of VTE but are significantly expensive
when routinely used across a hospital and may be associated
with transmission of infection. Intermittent pneumatic
compression devices are probably more effective than pas-
sive compression devices, but they are expensive and are
generally poorly used in hospitalized patients. Furthermore,
reuse of intermittent compression device bladders may be
associated with infectious diseases such as methicillin-
resistant Staphylococcus aureus. There is no high-quality
evidence by which to gauge the effectiveness of intermittent
pneumatic compression devices in medically ill patients.
Pharmacologic prophylaxis generally consists of heparin
or LMWH administered twice or three times daily. There is
clear evidence that, in high-risk patients, pharmacologic
prophylaxis reduces the risk of symptomatic DVT, PE, and
fatal PE. However, there have been no studies demon-
strating the effectiveness of these agents in the low-to-
moderate-risk patient.
Irrespective of the indication, there is clear evidence that
anticoagulants administered at prophylactic doses increase
the risk of major bleeding. Major bleeding is expensive to
treat and may be fatal in rare cases.
Modeling of the impact of prophylaxis provision on
low-to-moderate-risk patients suggests that the risk of PE
and fatal PE is low and very low, respectively. Although it
is logical to assume that pharmacologic prophylaxis would
further reduce the risk of thrombosis, there is also little
doubt that prophylaxis would increase the risk of major and
fatal bleeding. Rough modeling suggests, in fact, that, in
low-risk patients, provision of prophylaxis would actually
cause more fatal bleeding episodes than it prevented
through reduced risk of PE. Additionally, the routine use of
prophylaxis increases direct drug acquisition costs and
dramatically increases the costs associated with the man-
agement of bleeding complications.
Based on the lack of evidence of efficacy, indirect but
highly suggestive evidence of toxicity, a likely adverse
cost-effectiveness profile, and the possibility that prophy-
laxis delivered to low-to-moderate-risk patients may actu-
ally increase the risk of death, it is clear that it is
inappropriate to recommend VTE prophylaxis uniformly
for medical patients.
Thromboprophylaxis: the case for
Pulmonary embolism is among the leading causes of death
among patients hospitalized for acute medical illness.
Although effective mechanical and pharmacologic modal-
ities are available to reduce the risk of PE and DVT, cli-
nicians often do not employ VTE prevention strategies for
at-risk patients admitted with nonsurgical illnesses. The
reasons for this underutilization of effective prophylaxis
are not known with certainty; however, there are probably
many factors involved. First, the physician caring for a
patient with acute medical illness can easily be distracted
by many other demands for his/her attention; VTE pre-
vention can easily be forgotten. Second, a validated, user-
friendly scheme by which medical patients can be stratified
according to VTE risk does not exist. In light of the
potential for ‘‘sensory overload’’ among inpatient physi-
cians and the lack of an easy-to-use risk assessment model,
it is unreasonable to expect health care providers reliably to
prescribe prophylaxis against VTE to at-risk patients.
Cost is not a reason to oppose the routine use of VTE
prevention strategies among medical patients. UFH and
graduated compression stockings are relatively inexpen-
sive, and there is high-quality evidence that both will
reduce the risk of symptomatic DVT and PE. The absolute
risk of major bleeding is not substantially increased by the
use of low-dose anticoagulants (e.g., LMWH, fondapari-
nux, UFH) in this population. In other words, because of
low baseline risk of bleeding in this population, it is likely
that well over 100 patients would have to be treated with
low-dose anticoagulants (versus nothing) to cause one
additional major hemorrhage. While it would certainly be
reasonable to withhold anticoagulants from a patient at
high risk for bleeding (e.g., a cancer patient with profound
thrombocytopenia), the ‘‘default’’ position should be to
provide VTE prophylaxis to all medical patients because:
1) even patients at high risk for bleeding can benefit from
mechanical interventions, and 2) for the vast majority of
patients at ‘‘average’’ risk for bleeding, the trade-off will
favor low-dose anticoagulants.
Triple therapy: patients with CAD and AF
Patients with cardiovascular disease may have several
concomitant indications for antithrombotic therapy
including ACS, DVT and PE, mechanical valves, AF, and
coronary stent implantation. Overlapping indications for
antithrombotic therapy may lead to the need for ‘‘triple
therapy,’’ defined here as aspirin, clopidogrel, and oral
anticoagulation.
As the population ages, more patients will have both
ACS and AF; accordingly triple therapy may be used more
frequently. Prior studies have shown that, with more anti-
thrombotic therapy, risk of bleeding increases. Many
antiplatelet and anticoagulant drugs are part of the foun-
dation for treatment of ACS and AF, making the decision
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about the right combination of these agents challenging.
However, limited evidence is available to guide therapeutic
decision-making about triple therapy. Registry information,
subgroup analyses from clinical trials, and overviews of
single-center experiences have been published, but no
randomized trials evaluating different strategies of triple
therapy have been completed.
Multiple guidelines and consensus statements from
national societies provide recommendations for clinicians
concerning the use of triple therapy. A simple flow diagram
can be used by physicians to guide decisions about the need
for dual antiplatelet therapy or triple therapy based on the
assessment of patient bleeding and stroke risk. Five addi-
tional factors should be considered: 1) use of the lowest
dose of antiplatelet therapy; 2) use of bare metal stents
versus drug-eluting stents to minimize the duration of
antiplatelet therapy; 3) optimal INR within a range of
2.0–2.5; 4) gastric protection with PPIs; and 5) minimiza-
tion of the duration of triple therapy. It is also important to
re-evaluate regularly the need for triple therapy. The risk of
stent thrombosis will decrease over time, whereas bleeding
risk will remain constant.
Two ongoing randomized clinical trials will evaluate the
role of triple therapy: the What Is the Optimal Antiplatelet
and Anticoagulant Therapy in Patients with Oral Antico-
agulation and Coronary Stenting (WOEST) study
of * 500 patients post-stenting randomized to triple ther-
apy versus dual therapy (clopidogrel and an oral antico-
agulant) and the Intracoronary Stenting and Antithrombotic
Regimen: Testing of a Six-Week Versus a Six-Month
Clopidogrel Treatment Regimen in Patients With Con-
comitant Aspirin and Oral Anticoagulant Therapy Fol-
lowing Drug-Eluting Stenting (ISAR-Triple) trial of *600
patients post-drug-eluting stent implantation randomized to
triple therapy for 6 weeks versus triple therapy for
6 months.
Several new antiplatelet and anticoagulant agents are
also being studied for ACS and AF, including the PAR-1
inhibitors in the Thrombin Receptor Antagonist for Clini-
cal Events Reduction (TRACER) and TRA-2P programs;
factor Xa inhibitors in the Anti-Xa Therapy to Lower
Cardiovascular Events in Addition to Aspirin with or
without Thienopyridine Therapy in Subjects with Acute
Coronary Syndrome-Thrombolysis In Myocardial Infarc-
tion 46 (ATLAS ACS-TIMI 46) and the Apixaban for
Prevention of Acute Ischemic Events (APPRAISE)-2 ACS
trials; and factor Xa inhibitors in the Global Study to
Assess the Safety and Effectiveness of DU-176b versus
Standard Practice of Dosing with Warfarin in Patients with
Atrial Fibrillation (ENGAGE AF-TIMI 48), Apixaban for
the Prevention of Stroke in Subjects with Atrial Fibrillation
(ARISTOTLE), and the Efficacy and Safety Study of
Rivaroxaban with Warfarin for the Prevention of Stroke
and Non-Central Nervous System Systemic Embolism in
Patients with Non-Valvular Atrial Fibrillation (ROCKET
AF) trials. The future will be interesting. Triple therapy
may actually be redefined in the future with new P2Y12
inhibitors such as prasugrel and ticagrelor, oral factor Xa
inhibitors, and antithrombin agents. Indeed, warfarin may
become obsolete in patients with ACS and AF. In addition,
triple therapy may be replaced by ‘‘quadruple therapy’’
with aspirin, the P2Y12 inhibition, PAR-1 inhibition, and
oral anticoagulants.
Measuring quality in atrial fibrillation
Atrial fibrillation is a major health concern as assessed by
almost any metric. Over 3 million U.S. citizens have AF, a
number that is expected to nearly double by the year 2050.
Patients with either paroxysmal or persistent AF have
three-to-five-fold increased risk for stroke, and AF
accounts for up to 75,000 strokes per year (15% of all U.S.
strokes). Furthermore, those with AF have significantly
higher mortality and lower quality of life than those
without.
Treatment of AF is complex but centers on two major
goals: reducing patients’ embolic risk and controlling their
symptoms. Oral anticoagulant therapies (e.g., VKAs like
warfarin) are extremely effective in reducing patients’ risk
for stroke. However, the use of warfarin is complex and
concomitantly can increase patients’ risk for bleeding
events. Thus, warfarin use is reserved for those with at least
moderate stroke risk.
Current American College of Cardiology/American
Heart Association (ACC/AHA) AF performance indicators
include assessing the thromboembolic risk (CHADS score),
initiating warfarin in those with moderate or high risk, and
then closely monitoring warfarin therapy to ensure that
patients are in a narrow therapeutic range. Opportunities
for improvement on each of these performance metrics
abound. Depending on the study, only about 30–60% of
eligible AF patients in community practice actually receive
warfarin therapy. Those at highest risk, as assessed by the
CHADS score, are paradoxically less likely to receive
warfarin therapy. And even when instituted, time-in-ther-
apeutic range (TTR)—an important indicator of warfarin’s
safety and effectiveness—ranges from 30 to 60% in com-
munity case series. Newer agents, such as the oral direct
thrombin and factor Xa inhibitors, represent a major leap
forward for antithrombotic therapy for AF. These new drug
classes offer easier patient management without constant
drug monitoring. Furthermore, relative to warfarin, these
new drugs are being demonstrated to have similar or
improved thrombotic protection and significantly better
safety profiles.
III International Symposium of Thrombosis and Anticoagulation 257
123
The second goal of AF management is to control patient
symptoms and improve quality of life. Rhythm control of
AF, either with anti-arrhythmic drugs or with AF ablation
procedures, can restore sinus rhythm in many patients with
AF. However, studies to date in mildly symptomatic
patient subgroups have had difficulty showing that resto-
ration of sinus rhythm necessarily improves quality of life
or reduces stroke risks; further research is needed.
New anticoagulants for stroke prevention in atrial
fibrillation
Warfarin is effective for stroke prevention in AF but has
limitations because of variability in response and an
increased risk of bleeding. The most feared complication of
warfarin is intracranial bleeding. The efficacy and safety of
warfarin is related to the TTR, which is an INR of 2.0–3.0;
there is an increased risk of stroke and death at INR \ 2
and of bleeding at INR [ 3. However, the risk of bleeding,
including intracranial bleeding, is present also in patients
within the target range. This limits the indication for
warfarin to patients with an intermediate-to-high risk of
stroke (i.e., with a CHADS2 risk score above 1) to maintain
the net clinical benefit.
Therefore, development of new oral anticoagulants aims
to demonstrate that they are at least as effective as warfarin
and with better safety, allowing use in lower-risk popula-
tions. The new alternatives provide more specific inhibi-
tion of the coagulation cascade (i.e., by inhibition of
thrombin [dabigatran] or factor Xa [apixaban, rivaroxaban,
edoxaban, betrixaban]). Currently, the final results from
prospective trials comparing these new treatment alterna-
tives to warfarin in patients with AF and an increased risk
of stroke are available for dabigatran from the pivotal
Randomized Evaluation of Long-term Anticoagulant
Therapy Warfarin Compared with Dabigatran (RE-LY)
trial performed with a PROBE design. However, pro-
spective double-blind trials comparing apixaban and riva-
roxaban, respectively, with warfarin in similar populations
have been presented or will be presented within the next
year.
The ROCKET AF trial was presented at the AHA Sci-
entific Sessions in November 2010. This study was a pro-
spective, randomized, double-blind, double dummy,
parallel-group, multicenter, event-driven non-inferiority
study comparing the safety and efficacy of dose-adjusted
warfarin with rivaroxaban 20 mg once daily. The primary
efficacy end point for non-inferiority in ROCKET AF was
the composite of stroke (ischemic and hemorrhagic) and
non-central nervous system systemic embolism. The rate of
primary outcome per 100 patient-years was 2.12 in the
rivaroxaban arm compared with 2.42 in the warfarin arm
(P = 0.117 for superiority, P \ 0.001 for non-inferiority).
Rivaroxaban also had a slightly better mortality profile:
582 deaths versus 632 in the warfarin group, but the dif-
ference was not statistically significant. In a per-protocol
analysis, rivaroxaban was superior to warfarin with a pri-
mary outcome rate of 1.71 per 100 patient-years versus
2.16 (P = 0.018 for superiority and P \ 0.001 for non-
inferiority). Importantly, patients treated with rivaroxaban
had fewer intracranial hemorrhages (0.49 vs. 0.74%,
P = 0.019), fewer critical organ bleeds (0.82 vs. 1.18%,
P = 0.007) and lower bleeding-related deaths (0.24 vs.
0.48%, P = 0.003) than those on warfarin. Rivaroxaban
was well tolerated in the study, and rates of discontinuation
due to adverse events were similar to those seen for
patients on warfarin. One major criticism of the study was
the poor INR control compared with previous AF trials.
Among warfarin patients, the median time spent within
therapeutic range was just 57.8%; they were above thera-
peutic range 11.9% of the time and below range 19.7% of
the time. The results of the study are not published yet.
The RE-LY trial randomized 18,113 patients with AF in
951 sites to blinded fixed doses of dabigatran 110 mg or
dabigatran 150 mg twice daily versus unblinded warfarin
dose adjusted to INR 2.0–3.0. Median follow-up was
2 years. Rates of the primary outcome were 1.70% per year
on warfarin versus 1.55% per year on dabigatran 110 mg
(P non-inferiority \ 0.001) and 1.11% per year on dabig-
atran 150 mg (P superiority \ 0.001). Rates of major
hemorrhage were 3.46% per year on warfarin versus 2.74%
per year on dabigatran 110 mg (P = 0.002) and 3.22% per
year on dabigatran 150 mg (P = 0.32). Rates of hemor-
rhagic stroke were 0.38% per year on warfarin versus
0.12% per year on dabigatran 110 mg (P \ 0.001) and
0.10% per year on dabigatran 150 mg (P \ 0.001). Mor-
tality rates were 4.13% per year on warfarin versus 3.74%
per year on dabigatran 110 mg (P \ 0.12) and 3.63% per
year on dabigatran 150 mg (P \ 0.047).
Continued analyses of the RE-LY database have inves-
tigated the relative effects of dabigatran in relation to the
average time in therapeutic range (cTTR) in each center’s
warfarin population and to CHADS2 score. The quartiles of
cTTR for the warfarin patients were \57, 57–65, 65–73,
and [73%. There were no significant interactions with
cTTR concerning the superiority of dabigatran 150 mg or
the non-inferiority of dabigatran 110 mg versus warfarin
for prevention of stroke and systemic embolism and both
doses’ superiority concerning intracranial bleeding. With
dabigatran 150 mg, there was less major bleeding and
lower but similar bleeding at higher quartiles of cTTR,
while the rates of major bleeding were lower with dabig-
atran 110 mg irrespective of cTTR. Total mortality was
lower with both dabigatran doses at lower cTTR levels and
similar at higher cTTR levels.
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In the RE-LY trial, around one third of patients had
CHADS2 scores 0–1, 2, or 3–6. Increasing CHADS2 scores
were associated with increased risks for stroke, bleeding,
and mortality, with consistent benefits of dabigatran across
all CHADS2 risk groups above 0. Also, patients with the
highest risk for new events (i.e., those with previous stroke)
had consistent benefits with dabigatran versus warfarin.
Recently, the Apixaban versus Acetylsalicylic Acid to
Prevent Strokes (AVERROES) trial compared the factor
Xa inhibitor, apixaban (5 mg b.i.d.), with aspirin
(80–325 mg/day) for stroke prevention in patients with AF
who were unsuitable for oral anticoagulation. The trial was
prematurely terminated because apixaban was found
superior to aspirin in prevention of the primary end point of
stroke and systemic embolism: there was a 54% reduction
(P \ 0.001) at a mean follow-up of 1.1 years. There was
no significant difference in major bleeding or any other
major safety end point. Apixaban was better tolerated than
aspirin, with fewer discontinuations of apixaban compared
with aspirin (RR 0.88, 95% CI 0.78–1.00, P = 0.04).
In summary, for patients with AF, direct thrombin
inhibition with dabigatran provides an attractive alternative
to warfarin therapy that preserves or improves on the
reduction in stroke and systemic embolism achievable with
warfarin with similar to lower rates of major hemorrhage.
Factor Xa inhibition with apixaban offers a superior
alternative to aspirin for stroke prevention in AF patients
who are not candidates for warfarin, with even better tol-
erance than aspirin. The role of rivaroxaban or apixaban in
treatment of warfarin-eligible patients awaits peer-
reviewed data from ongoing or recently completed studies.
Therefore, there is great hope that soon several new
treatment alternatives will be available for stroke preven-
tion in AF that should improve both patient outcomes and
quality of life.
The relative importance of stroke and bleeding risk
in patients with AF: a case-based approach
You are seeing a new patient in clinic. She is an 82-year-
old female with hypertension, diastolic heart failure, and
non-valvular AF. She has no idea how long she has been in
AF, and she reports no change in her symptoms. Her heart
rate is irregular, 85 beats per minute, and her blood pres-
sure is 130/80 mmHg. She asks, ‘‘Should I start warfarin?’’
Initially, this seems like a relatively easy question; how-
ever, the decision to start a patient on life-long anticoag-
ulation requires a careful assessment of benefits and risks
of anticoagulation and consideration of how this informa-
tion should be used for an individual patient.
Evidence-based medicine, as described by David Sack-
ett, is the process of combining quantitative evidence about
medical practice with expert physician judgment to ensure
each individual patient the best medical care with repro-
ducible high quality. To provide evidence-based throm-
boembolism prophylaxis in patients with AF, one has
to carefully consider the benefits of thromboembolism
prophylaxis (primarily a reduction in the risk of thrombo-
embolic stroke) and the risks of thromboembolism pro-
phylaxis (primarily an increase in the risk of bleeding).
These population-based benefits and risks then need to be
applied to the individual patient.
The absolute risk of stroke in patients with AF is less
related to the burden of AF and more related to patient
comorbidities. A number of risk scores have been devel-
oped. The most common is the CHADS2 score, which
assigns one point for heart failure, hypertension, age [
75 years, and diabetes, and two points for prior stroke. The
risk of stroke increases with increasing CHADS2 score,
from roughly 2% per year for CHADS2 scores of 0–1 to
over 15% per year for CHADS2 scores of over 6. A newer
score, the CHADS-VASC, includes points for female sex,
vascular disease, and age between 65 and 75 years, and
assigns two points for age [ 75 years. The CHADS-VASC
score better stratifies risk in patients with a CHADS2 score
of 0. Our patient has a CHADS2 score of 3 and a CHADS-
VASC score of 4. Based on this, her annual risk of stroke is
6–8%. She says, ‘‘I’m old and understand I have a risk of
stroke, but should I take warfarin?’’
There are two additional important factors that have to
be incorporated when considering the potential benefits of
warfarin for this patient. The first is just how bad a stroke is
likely to be and the second is whether warfarin will be
effective at reducing the risk of stroke. The definition of
stroke used in most of the clinical trials of thromboembo-
lism prophylaxis in patients with AF is non-traumatic, focal
neurologic deficit lasting at least 24 h. Thus, some strokes
are devastating, while others result in no long-term deficit.
However, strokes in patients with AF tend to be severe,
with more than two-thirds resulting in death or permanent
disability. Also important is that warfarin is highly effec-
tive at reducing strokes in patients with AF. Treatment with
warfarin results in a roughly two-thirds reduction in stroke.
Therefore, our patient has a more than 4% risk per year of a
disabling stroke, and her risk of stroke could be reduced to
roughly 2% with warfarin.
Warfarin, a potent anticoagulant, has bleeding as its
major side effect. Warfarin is most effective in patients
who maintain an INR between 2 and 3. With an INR
below 2, the risk of stroke promptly increases. With an
INR above 3, the risk of bleeding increases. However,
even with reasonably good INR control, patients taking
warfarin have a roughly 2% annual risk of major bleed-
ing. The risk factors for bleeding substantially overlap
with the risk factors for stroke. The recently developed
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HAS-BLED score assigns one point each for hyperten-
sion, abnormal renal function, abnormal liver function,
prior stroke, a history of bleeding, poor INR control,
age [ 65 years, and drug and alcohol use. The risk of
bleeding ranges from 1% with a HAS-BLED score of 0 to
more than 15% with a HAS-BLED score of 5. Our patient
has a HAS-BLED score of 2 or more; thus, an annual risk
of major bleeding on warfarin of 3% or more. She asks,
‘‘How bad is major bleeding?’’
Like stroke, it is important to consider the range of
major bleeding. The definition of major bleeding in most
clinical trials of thromboembolism prophylaxis in patients
with AF is that of the International Society of Thrombosis
and Hemostasis (ISTH). ISTH major bleeding includes
fatal bleeding, symptomatic intracranial, intra-articular,
intra-spinal, pericardial, intraocular, retroperitoneal, or
intramuscular bleeding with compartment syndrome, or
bleeding resulting in a fall in hemoglobin of at least 2 g/dl
or leading to transfusion of two or more units of red blood
cells. In the recently reported RE-LY trial, the rate of major
bleeding with warfarin was 3.6%, while the rate of the most
devastating intracranial bleeding was only 0.7%. These
were in contrast to a stroke rate of 1.6%. Intracranial
bleeding is consistently associated with much worse out-
comes than other types of major bleeding. When one
considers a ‘‘net clinical benefit’’ that includes reduction in
stroke and increase in only intracranial bleeding, those
patients with a CHADS2 score of 2 or more have a sig-
nificant benefit with warfarin. This includes our patient
above who, with a CHADS2 score of 3, would be expected
to have a net benefit of roughly 2% per year with warfarin.
Now that we have covered the major efficacy and safety
issues with warfarin, our patient asks, ‘‘Are there are any
other downsides to warfarin?’’
Warfarin, although one of the most effective drugs
available to prevent devastating consequences of atrial
fibrillation, also has significant downsides beyond bleed-
ing. Warfarin has a host of dietary and drug interactions
and requires at least monthly INR monitoring; many
patients are plagued by significant INR variability requir-
ing frequent dose changes. Finally, and perhaps most
importantly, the dietary and drug interactions and the need
for frequent monitoring create a constant worry on both the
part of the patient and his or her physician. It is for these
reasons that warfarin isn’t used in close to half of patients
with AF, including many of those who are at the highest
risk of stroke. Fortunately, for all patients with AF, there
are a host of alternatives to warfarin, including factor X
and factor II (thrombin) inhibitors that are in development.
Some of these may offer better efficacy and/or safety than
warfarin, but all are likely to result in less worry; thus,
hopefully, we will see more use of effective thromboem-
bolism prophylaxis in patients with AF. Based on this
discussion, our patient has decided to start warfarin as
thromboembolism prophylaxis, at least until one of these
alternative anticoagulants is available.
The anticoagulation of STEMI patients not eligible
for reperfusion
In clinical practice, approximately 30% of patients with
STEMI will not receive reperfusion therapy, either by
primary PCI or lytics, because of delayed presentation,
increased risk of bleeding, or patient-related factors. Sys-
temic anticoagulants have been tested in this setting as a
way to reduce the occurrence of adverse events, including
mortality and re-infarction. A limited number of contem-
porary trials are available to guide clinical decision-mak-
ing; however, there is no clear consensus on the use of
systemic anticoagulation in this setting.
In a post-hoc analysis of the Thrombolysis in Myo-
cardial Infarction (TIMI) 11B and Efficacy and Safety of
Subcutaneous Enoxaparin in Non-Q wave Coronary
Events (ESSENCE) trials, of the 7081 patients initially
identified as having non-STEMI, 252 were subsequently
found to have Q-wave MI. When treated with enoxaparin
instead of UFH, these patients had 28% less death, MI,
and recurrent angina at 30 days (P = 0.04). These results
prompted the Treatment of Enoxaparin and Tirofiban in
Acute Myocardial Infarction (TETAMI) trial, which, to
this day, remains the only prospective randomized con-
trolled trial specifically testing anticoagulation strategies
in STEMI patients not eligible for early reperfusion ther-
apy. TETAMI compared the efficacy and safety of enox-
aparin versus UFH and eptifibatide versus placebo in a
factorial design. In this context, enoxaparin and UFH were
equivalent in terms death, re-infarction, or recurrent
angina at 30 days (15.7 vs. 17.3%, respectively;
OR = 0.89, 95% CI 0.66–1.21, P = NS). Tirofiban was
not superior to placebo to improve outcome and tended to
increase the rate of major bleeding.
In a more contemporary setting, the randomized double-
blind OASIS-6 trial compared fondaparinux with UFH or
placebo in STEMI patients, some of whom who were not
eligible to receive reperfusion. In this subgroup, fonda-
parinux was better than either UFH or placebo at reducing
the occurrence of death or MI at 30 days (12.2 vs. 15.1%,
P = 0.04). Interestingly, the rate of major bleeding among
patients treated with fondaparinux was similar to controls
(hazards ratio = 0.84, 95% CI 0.47–1.50, P = 0.55).
Despite our best efforts, a significant proportion of
patients do not receive reperfusion therapy. In 2010, we
don’t know with certainty that anticoagulation is superior
to no anticoagulation in patients with STEMI not eligible
for reperfusion.
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Antiplatelet therapy in patients undergoing CABG
surgery: what should we do?
Antiplatelet therapy significantly reduces mortality in ACS.
However, a problem is posed when patients on antiplatelet
therapy require cardiac surgery, as this represents a rec-
ognized risk for increased surgical blood loss. Formerly,
aspirin was suspended for 5 days before surgery; in recent
years, this approach has not been routinely followed. In
fact, some centers introduce aspirin before surgery, espe-
cially when an off-pump technique is employed. The same
practice of introducing aspirin before surgery does not
occur with clopidogrel, which is most widely used in ACS
after drug-eluting stent implantation and before primary
PCI for MI. Clopidogrel is administered in emergency
rooms when ACS is suspected, even before a definitive
diagnosis is made. It permanently blocks platelets, and its
effect only diminishes after the natural platelet replace-
ment, which takes 5–7 days in a normal subject. CABG
surgery should be avoided during this period, but this is not
strictly observed in practice, nor is it clear the magnitude of
the contribution of clopidogrel to surgical bleeding. Short-
acting and reversible antiplatelet drugs, such as ticagrelor
(oral) and cangrelor (intravenous), are being introduced,
but they are not yet in general clinical practice. Abciximab,
a humanized monoclonal antibody to the platelet GP IIb/
IIIa receptor, irreversibly binds the receptor, has a more
intensive antiplatelet effect, and should be avoided before
surgery. However, the small-molecule GP IIb/IIIa inhibi-
tors (eptifibatide and tirofiban) reversibly bind the receptor,
have short half-lives, and have not been shown to increase
CABG-related bleeding.
Most guidelines and practicing cardiac surgical centers
recommend stopping clopidogrel administration for 5 days
before elective surgery. In one multicenter analysis,
exposure to clopidogrel within 5 days before CABG was
associated with a 9.8-fold increase in need for reoperation
(P \ 0.01). However, other analyses have found weaker or
no relationship with reoperation. In urgent situations, the
risk of MI or its extension must be balanced against the risk
of surgical bleeding, increased morbidity, and possible
mortality. Intravenous UFH, on the other hand, could be
safely and efficaciously introduced instead of clopidogrel
in emergency situations, until a coronary artery anatomical
diagnosis is obtained and a decision for PCI or CABG is
made. One strategy commonly used is to not administer
clopidogrel or prasugrel until the anatomy is known in
STEMI patients. However, in NSTE ACS patients, the
overall rate of CABG is only 10–15%, and there are no
effective methods to predict at presentation who those
individuals will be. Thus, the ischemic benefits of early
treatment in this situation may outweigh the downsides of
delay to CABG if it is ultimately indicated.
In the unstable patient with severe proximal coronary
artery lesions, when surgery must be performed in the
presence of clopidogrel, some adjuvant measures for better
hemostasis may be considered, though few data are avail-
able for their effectiveness. These include careful surgical
evaluation, the use of prophylactic antithrombotic agents,
such as epsilon-aminocaproic acid or tranexamic acid (not
aprotinin), during and after the procedure, and platelet
infusion.
Statistical issues in the design and analysis of clinical
research
As new drugs and devices are developed, questions arise as
to the efficacy and safety of these treatments overall and
relative to other available treatments, as well as to which
patient populations would benefit most from the new
therapy. The ideal situation for answering these questions
would be to treat the entire population of eligible patients
and observe all responses. But it is usually impossible to
treat and evaluate every possible patient. Instead, we study
the use of the therapy in a sample of the population. Based
on the results observed in the sample, we make inferences
about what we would expect to see if we could have
applied the treatment to the entire population.
Multiple aspects of research determine the level of
confidence one can have that the results observed in the
sample are real and not just an anomaly of that sample or
experiment. The number of patients studied must be large
enough to provide adequate power to detect a significant
difference. The patients studied should be generalizable to
the population of interest. The allocation of treatment to the
patients must be in a random fashion to ensure no biases
are introduced during the selection process. The blinding of
treatment is another important step in eliminating bias.
When possible, the treating physician, the patient, and all
others involved in the study should be blinded to the
treatment that the patient is receiving.
All aspects of the study should be clearly specified and
well-defined. When possible, the actual end point of
interest should be studied rather than a surrogate end point.
For the end point, the definition should be explicitly
described, thus allowing for reproducibility in future
studies. The protocol should state upfront whether the
results will be based on the enrolling physician’s deter-
mination, independent core laboratory results, or an inde-
pendent adjudication committee determination of the end
point. The timing of the end point should be based on
clinical relevance. With long-term outcomes, the short-
term results are also known. But the treatment may only
affect outcomes acutely, so results may become diluted
after an extended period of time.
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Randomization of the treatment of interest is not always
possible. There are situations in which randomization
would be unethical and/or impossible to implement. In
these cases, we must instead study series of patients and
use special statistical tools to account for biases. These
include adjusting for confounders or for the propensity to
receive one treatment versus another. If the modeling
process can fully adjust for all of the factors that are
associated with receiving the treatment and with the out-
come of interest, then one can make causal inferences.
However, this situation is seldom possible.
With multiple treatments for the same condition, the
growing increase of genetic markers, globalization of
clinical trials, and many changes in research over the past
few years, the analytic issues have become increasingly
complex. Statistical expertise is needed to ensure high-
quality, accurate results. A greater understanding of the
underlying statistical issues in clinical research is needed
for the non-statistician, who must critically review and
incorporate this ever-growing wealth of clinical
information.
Globalization of clinical research
Cardiovascular disease accounts for at least 30% of deaths
worldwide (16.6 million people estimated in 2002). Nota-
bly, the majority of these individuals are in the low- and
middle-income brackets, reaffirming that this is not only a
disease of the rich. Projections by Beaglehole and Bonita
indicate a growing cardiovascular burden across all income
groups such that it is estimated that over three quarters of
all deaths will occur secondary to chronic non-communi-
cable disease by the year 2030. Of these non-communi-
cable diseases, cardiovascular disease will be the most
dominant. The socioeconomic determinants of this trend
provide a compelling impetus to invest in research on
health policy and integration of health systems that will
enhance the application of available knowledge and close
the treatment gaps that exist.
Remarkably, the cost of care bears little relationship to
life expectancy: in this regard, the average per capita
expenditure across a wide spectrum of countries is $2986
with an average life expectancy of approximately 79 years.
At the extremes, Mexico spends slightly more than $800
and the United States in excess of $7000 per capita, yet
both have below-average life expectancies indicating the
complexity of this relationship. Notably, the Scandinavian
countries, Canada, Switzerland, Australia, and France
expend more than the median amounts but also have life
expectancies in excess of the average.
The Treatment and Outcomes of Acute Coronary Syn-
dromes in India (CREATE) registry offers insight into
some of the challenges facing global cardiovascular
research. It highlights the relatively young age at which MI
occurs, the still dominant incidence of STEMI versus non-
STEMI, with mortality from STEMI in excess of 8%.
Remarkably, there is a delay from symptom onset to hos-
pitalization of approximately 5 h for STEMI patients and
an additional delay from hospitalization to fibrinolysis of
nearly 1 h. The large majority of patients are transported to
hospital by taxi or private vehicle, but as many as a third
use public transportation and only a minority have access
to ambulance transportation. As communicated by Pra-
bhakaran, several factors impair research progress in India,
including an entrenched bureaucracy, a lack of interdisci-
plinary and transdisciplinary research, resistance to change
across all levels, substantial mobility and instability of the
trained workforce, and the dominance of commercial
contract research organizations (CROs) with a profit
mandate.
On a broader global scale, perverse economic incentives
exist in the provision of health care, and there remain huge
disparities in access to high-quality health care. Moreover,
the chasm between what we know versus how we integrate
knowledge, coupled with fear of liability and a sometimes
unreasonable quest for diagnostic certainty, contribute to
inefficiencies. The treatment-risk paradox is pervasive,
and too many dollars are spent on marginal gains or the
so-called ‘‘flat portion’’ of the cost–benefit curve.
It is reassuring that there appears to be a renewed
understanding of the importance of global academic col-
laboration based on several factors, including information
technology and its transformation of the world into a global
village. Moreover, there is a commonality of health-related
issues and increasing concern about the costs of health
care, which are driving an effort to acquire the best metrics
for demonstration of return on investment in health care
costs. An increasing number of questions regarding com-
parative efficacy that require head-to-head evaluations
ensures no lack of meaningful projects to undertake. As
mortality declines and life expectancy increases in a
number of countries, new emphasis on better metrics to
assess quality of life has emerged. Striking a balance
between the content of care and elements associated with
human behavior that contribute to the epidemics of obesity
and diabetes remains a major challenge. In this regard,
better understanding of the future of personalized medicine
and genomics versus broad population approaches is
mandatory. An important caveat for research in the
developing world relates to statements by both the World
Health Organization and the World Medical Organization
affirming that, when conducting research in developing
countries, it is necessary to ensure that the results of the
research will be applicable to those populations in whom it
is conducted so that they can benefit from the results.
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As one surveys the global treatment gap, it is sobering to
contemplate that\10% of global health research is devoted
to diseases comprising 90% of the global disease burden.
Indeed, a third of the world’s population receives only 2%
of global health resources, and only 5% of health research
is devoted to prevention resources versus 95% dedicated to
treatment. Daar et al. highlight six key challenges in
tackling chronic non-communicable disease: (1) raising
public awareness; (2) enhancing economic, legal, and
environmental policies; (3) modifying risk factors; (4)
engaging businesses and community; (5) mitigating health
impacts of poverty and urbanization; and (6) reorienting
health systems.
The VIGOUR Group is well prepared to execute its
mission of enhancing worldwide cardiovascular health by
the creation, implementation, and evaluation of novel
strategies developed through global collaboration. Shared
perspectives among group members relate to a strong
social conscience and recognition of partnership within a
global village. Not only is there an appreciation of the
profound unmet needs that exist but also of the mismatch
between resources on health expenditures versus key
unanswered research questions. In a recent publication by
Califf et al. from the VIGOUR Group, four key issues were
identified: (1) the lack of definitive evidence to guide care,
(2) disease heterogeneity, (3) inadequate funding, and (4)
paucity of new leadership. To foster global academic col-
laboration, infrastructure at all health professional levels is
needed, fiscal transparency and stability of academic
research organizations (AROs) are required, and the right
balance must be struck between individual versus group
rewards for achievement. There is a compelling need to
develop new leaders and define an appropriate career path
for those engaging in these efforts. Each of these issues is
associated with opportunities and strategies that will help
to drive the cycle of quality on a global basis.
Role of AROs
Conducting high-quality global clinical research is
increasingly challenging. The world is ‘‘flattening’’ (Tho-
mas L. Freidman) due to a variety of forces including
advances in information technology that allow efficient
sharing of data across the globe. However, multiple
impediments remain for efficient clinical trial conduct.
Most AROs have three key priorities: (1) patient care,
(2) education, and (3) research. These priorities are often
reflected in mission statements such as those from the Duke
Clinical Research Institute (DCRI), the Brazilian Clinical
Research Institute (BCRI), the Canadian VIGOUR Centre
(CVC), and the Uppsala Clinical Research Center (UCR).
The typical ARO will encompass a variety of research
initiatives, including clinical trials, registries, health eco-
nomics, quality-of-life projects, methodological research,
core laboratories, and education. These programs are sup-
ported by a framework of coordinating center services. By
contrast, missions of commercial CROs are different and
typically reflect a goal of maximizing returns or providing
efficient services. In a simplistic view, an ARO performs
research, and a commercial CRO performs research services.
The United States and many parts of the world are
experiencing a shortage of clinical trial investigators and
coordinators. Financial pressures and the demands of
clinical practice both are central issues of concern, along
with growing complexities involving contracts and regu-
lations, lack of training, and less infrastructure to support
site-based research at many institutions. Efforts are needed
to better understand local site challenges and to respond to
those challenges. The Clinical Trials Network, which
is part of the National Institutes of Health Roadmap
(www.ctnbestpractices.org), provides site investigators
with opportunities to learn and network in support of their
daily activities.
Cardiovascular disease is and likely will remain the
number one cause of death in the world; thus, identifying
new and promising therapies is critical. Large clinical
outcomes trials will remain the standard for assessing the
benefits and safety of new agents, and, as such, clinical
trials to evaluate novel therapies will remain large in size
and require a global effort. Global clinical research driven
by collaboration will be essential to complete these large
trials quickly and efficiently. Relationships such as those
that have been established between the DCRI and BCRI in
Sao Paulo, Brazil, will help create the foundation and
infrastructure for performing quality clinical research in the
future. Several key priorities for AROs include: (1) creat-
ing a culture of excellence and partnership; (2) evaluating
novel, efficient, and less costly trial designs and operations;
(3) promoting evidence-based medicine and evidence-
based trial operations; and (4) developing a sustainable
clinical research community through focused support of
site investigators. The future has challenges but also
exciting opportunities.
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